MyFinsight
Home
Compare
About
Recent SEC Filings
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Cash Flow Overview
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Stock-based compensation
Amortization of debt issuance co...
Others
Negative Cash Flow Breakdown
Net loss
Prepaid expenses and other curre...
Accrued liabilities
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-43,082
-53,458
-59,450
-56,755
Stock-based compensation
7,184
7,405
7,407
5,980
Non-cash operating lease expense
61
59
57
58
Depreciation and amortization
7
8
9
23
Net accretion of investments in marketable securities
0
0
137
612
Impairment of held for sale assets
0
-
217
0
Loss (gain) on disposal of property and equipment
0
71
15
-
Amortization of debt issuance costs and accretion of final payment fee
394
418
492
-
Non-cash interest expense and amortization of debt issuance costs
-
-
-
213
Amortization and write-off of deferred debt issuance costs
-
-
717
-
Other noncash expenses
-
-
-7
39
Prepaid expenses and other current assets
1,676
-1,644
3,555
326
Accounts payable
-909
1,678
2,830
-96
Accrued liabilities
-1,436
-4,020
3,980
4,865
Operating lease liabilities
-71
-67
-46
39
Other assets
-
-
0
-1
Net cash used in operating activities
-39,528
-46,404
-47,955
-46,633
Purchases of marketable securities
0
0
0
0
Cash paid for acquisition of assets
-
-
0
0
Proceeds from maturities of marketable securities
0
0
42,583
51,246
Proceeds from sale of equipment
0
71
47
87
Purchases of property and equipment
-
-
-
16
Net cash provided by investing activities
0
71
42,646
51,317
Proceeds from term loan, net
0
-
38,899
-136
Proceeds from exercise of stock options
-
-
0
0
Payment of debt issuance costs in connection with term loan amendment
445
-
-
-
Proceeds from employee stock purchase plan purchases
239
-
216
0
Payments for offering costs in connection with at-the-market offering and initial public offering
-
-
-
0
Proceeds from issuance of common stock in at-the-market transactions, net of commission and offering costs
9,496
10,875
19,653
-
Net cash provided by financing activities
9,290
10,875
58,768
-136
Net change in cash and cash equivalents
-30,238
-35,458
53,459
4,548
Cash and cash equivalents and restricted cash at beginning of year
147,072
182,530
129,071
143,361
Cash and cash equivalents at end of period
116,834
147,072
182,530
129,071
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
NMRA Cash Flow Sankey Diagram
Sankey diagram visualizing NMRA cash flow for the period
Proceeds from issuance of
common stock in...
$9,496K
Proceeds from employee
stock purchase plan...
$239K
(305.08%↑ Y/Y)
Net cash provided by
financing activities
$9,290K
(-49.67%↓ Y/Y)
Canceled cashflow
$445K
Net change in cash
and cash...
-$30,238K
(-60.52%↓ Y/Y)
Canceled cashflow
$9,290K
Stock-based compensation
$7,184K
(-56.43%↓ Y/Y)
Amortization of debt issuance
costs and accretion of...
$394K
Non-cash operating lease
expense
$61K
(-96.57%↓ Y/Y)
Depreciation and
amortization
$7K
(-96.02%↓ Y/Y)
Payment of debt issuance
costs in connection...
$445K
Net cash used in
operating activities
-$39,528K
(64.66%↑ Y/Y)
Canceled cashflow
$7,646K
Net loss
-$43,082K
(64.31%↑ Y/Y)
Prepaid expenses and
other current assets
$1,676K
(250.86%↑ Y/Y)
Accrued liabilities
-$1,436K
(69.12%↑ Y/Y)
Accounts payable
-$909K
(65.87%↑ Y/Y)
Operating lease
liabilities
-$71K
(96.21%↑ Y/Y)
Buy us a coffee
Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics, Inc. (NMRA)